L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
← catalyst calendarNCT07228442 · readout ≤ 1,654 d
Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
92estimated
Sites
19
Countries
Germany, Greece, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Feb 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced Cutaneous Squamous Cell Carcinoma
Intervention
- Drug: L19IL2/L19TNF
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (BORR)
measured From enrollment up to a maximum of 160 weeks after the start of treatment
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed